Archive
2024 – Going for Growth
This CRDG report written by Professor Trevor Jones CBE FMed Sci, George Freeman MP and Zack Bellman argues that the UK is in a strong position to compete and become the world leader in the research, development and commercialisation of pharmaceutical cannabinoids for a range of conditions.
The report makes ten recommendations for government and regulators; the scientific and research community; biotech and pharma investors; and charities.
The CRDG represents an evolution of The Centre for MC, which formed in November 2018. Below we present the reports that paved the way for the formation of CRDG.
2022 – Hodges Review
This review, overseen by Professor Christopher Hodges, assesses the UK’s legal cannabinoid industry and how public policy and regulation can support its growth. It contains 20 key recommendations to make the UK a global leader in cannabinoid innovation.
2022 – Decalogue
This report examines the evolving economic landscape in the UK amid the pandemic and post-Brexit period, emphasizing the growing interest in regulatory innovation to bolster the country’s competitive edge.
Three years after medicinal cannabis was first legalised in the UK, a diverse group of scientists, industry leaders, clinicians and campaigners came together at an event in London’s Kings College to argue for policy changes to promote better understanding of the benefits of medicinal cannabis, increased access to medicines for patients and regulations more conducive to institutional investment in the sector.
The accompanying report, Decalogue – Ideas to Increase Patient Access and Clinical Understanding of Medicinal Cannabis – sets out 10 new ideas in a series of essays.
2021 – Green Shoots: Sowing the Seeds of the New UK Cannabinoid Market
The “Green Shoots” paper presents a vision for the UK’s consumer cannabinoid and medicinal cannabis market. It offers 20 key recommendations aiming to promote innovation, reduce market obstacles, and enhance regulatory processes, ultimately strengthening the UK’s position in science and technology while supporting businesses, particularly startups and SMEs.
This report discusses the current state and future prospects of medicinal cannabis in the UK. It reviews the scientific and clinical evidence for its benefits, as well as the policy implications of its use. It also reports the findings of a national survey that estimates the number of people who use illegal cannabis for medical reasons, and the costs and risks associated with this practice.
This report discusses the background of the law change in 2018, to allow some doctors to prescribe Cannabis-based Medicinal Products (CBMPs) for some conditions, and makes recommendations for policy change moving forward to help foster this new fledgling industry.